An MD Anderson Cancer Center study discovered a cellular pathway tied to cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma.
The Oncologic Drugs Advisory Committee held its first session since President Trump’s inauguration, with a two-day, back-to-back marathon meeting, signaling a return to business at FDA after significant upheaval at the agency.
